Immunoregulatory functions of immune complexes in vaccine and therapy

EMBO Molecular Medicine

Volumn 8, Issue 10, 2016, Pages 1120-1133

  Wen, Yu mei ^a   Mu, Libing ^b   Shi, Yan ^b,c  

^a FUDAN UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

adjuvant; Fc R; immune complex; immune therapy; vaccine

Indexed keywords

FC RECEPTOR; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL PRACTICE; CROSS PRESENTATION; DRUG EFFICACY; HELPER CELL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; IN VIVO STUDY; INFECTION CONTROL; INFLAMMATION; INFLUENZA; LABORATORY TEST; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; VACCINATION; VIRUS INFECTION;

EID: 84989865076     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201606593     Document Type: Review

References (133)

1. Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F (2008) In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci USA 105: 15005–15009
2. Amigorena S, Bonnerot C (1999) Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 11: 385–390
3. Amigorena S, Savina A (2010) Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22: 109–117
4. Astry CL, Jakab GJ (1984) Influenza virus-induced immune complexes suppress alveolar macrophage phagocytosis. J Virol 50: 287–292
5. Bergtold A, Desai DD, Gavhane A, Clynes R (2005) Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23: 503–514
6. Berken A, Benacerraf B (1966) Properties of antibodies cytophilic for macrophages. J Exp Med 123: 119–144
7. Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL (2001) Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 101: 276–283
8. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun JJ, Gallo RC, Shearer GM, Zagury D (1988) Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 334: 706–708
9. Bohm S, Kao D, Nimmerjahn F (2014) Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. Curr Top Microbiol Immunol 382: 393–417
10. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815–824
11. Bonnerot C, Briken V, Brachet V, Lankar D, Cassard S, Jabri B, Amigorena S (1998) syk protein tyrosine kinase regulates Fc receptor gamma-chain-mediated transport to lysosomes. EMBO J 17: 4606–4616
12. Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R et al (2014) FcRgamma-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells. J Immunol 193: 5506–5514
13. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158: 1243–1253
14. Boyden SV, Sorkin E (1960) The adsorption of antigen by spleen cells previously treated with antiserum in vitro. Immunology 3: 272–283
15. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C et al, (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881–1893
16. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C (2007) Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316: 612–616
17. Celis E, Abraham KG, Miller RW (1987) Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 7: 563–568
18. Celis E, Chang TW (1984) Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 224: 297–299
19. Celis E, Zurawski VR Jr, Chang TW (1984) Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies. Proc Natl Acad Sci USA 81: 6846–6850
20. Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM (2006) Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 177: 8410–8421
21. Chatterjee B, Smed-Sorensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, Widger J, Keler T, Delamarre L, Mellman I (2012) Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 120: 2011–2020
22. Clatworthy MR, Aronin CE, Mathews RJ, Morgan NY, Smith KG, Germain RN (2014) Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med 20: 1458–1463
23. Cohn L, Chatterjee B, Esselborn F, Smed-Sorensen A, Nakamura N, Chalouni C, Lee BC, Vandlen R, Keler T, Lauer P et al (2013) Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med 210: 1049–1063
24. Copeman SM, O'brien RA, Eagleton AJ, Glenny AT (1922) Experiences with the Schick Test and Active Immunization against Diphtheria. Br J Exp Pathol 3: 42
25. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M et al (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351: 1339–1342
26. Devey ME, Steward MW (1980) The induction of chronic antigen-antibody complex disease in selectively bred mice producing either high or low affinity antibody to protein antigens. Immunology 41: 303–311
27. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125–133
28. DiLillo DJ, Ravetch JV (2015) Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell 161: 1035–1045
29. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B et al (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843–850
30. Giambrone JJ, Dormitorio T, Brown T (2001) Safety and efficacy of in ovo administration of infectious bursal disease viral vaccines. Avian Dis 45: 144–148
31. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104: 9422–9427
32. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 14: 94–108
33. den Haan JM, Bevan MJ (2002) Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 196: 817–827
34. Haddad EE, Whitfill CE, Avakian AP, Ricks CA, Andrews PD, Thoma JA, Wakenell PS (1997) Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis 41: 882–889
35. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U et al (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158: 989–999
36. Harbers SO, Crocker A, Catalano G, D'Agati V, Jung S, Desai DD, Clynes R (2007) Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117: 1361–1369
37. Hari A, Ganguly A, Mu L, Davis SP, Stenner MD, Lam R, Munro F, Namet I, Alghamdi E, Furstenhaupt T et al (2015) Redirecting soluble antigen for MHC class I cross-presentation during phagocytosis. Eur J Immunol 45: 383–395
38. Heesters BA, Chatterjee P, Kim YA, Gonzalez SF, Kuligowski MP, Kirchhausen T, Carroll MC (2013) Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 38: 1164–1175
39. Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE et al (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci USA 111: 5992–5997
40. Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA, Simon RE, Levy DN, Tuen M (2009) The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 28: 352–360
41. Hong Y, Peng Y, Mi M, Xiao H, Munn DH, Wang GQ, He Y (2011) Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine 29: 3909–3916
42. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M et al (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 110: 16538–16543
43. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ (2006) Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80: 8530–8540
44. Ivan J, Velhner M, Ursu K, German P, Mato T, Dren CN, Meszaros J (2005) Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can J Vet Res 69: 135–142
45. Jeurissen SH, Janse EM, Lehrbach PR, Haddad EE, Avakian A, Whitfill CE (1998) The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. Immunology 95: 494–500
46. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. Nat Rev Immunol 12: 557–569
47. Kalergis AM, Ravetch JV (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195: 1653–1659
48. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr SJ, Berger M, Petzold D et al (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 18: 1401–1406
49. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA et al (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118: 1700–1711
50. Kosco MH, Burton GF, Kapasi ZF, Szakal AK, Tew JG (1989) Antibody-forming cell induction during an early phase of germinal centre development and its delay with ageing. Immunology 68: 312–318
51. Kotsias F, Hoffmann E, Amigorena S, Savina A (2013) Reactive oxygen species production in the phagosome: impact on antigen presentation in dendritic cells. Antioxid Redox Signal 18: 714–729
52. Koyama A, Niwa Y, Shigematsu H, Taniguchi M, Tada T (1978) Studies on passive serum sickness. II. Factors determining the localization of antigen-antibody complexes in the murine renal glomerulus. Lab Invest 38: 253–262
53. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M et al (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678–682
54. Le Roux D, Lankar D, Yuseff MI, Vascotto F, Yokozeki T, Faure-Andre G, Mougneau E, Glaichenhaus N, Manoury B, Bonnerot C et al (2007) Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor. Mol Biol Cell 18: 3451–3462
55. Leon B, Ballesteros-Tato A, Randall TD, Lund FE (2014) Prolonged antigen presentation by immune complex-binding dendritic cells programs the proliferative capacity of memory CD8 T cells. J Exp Med 211: 1637–1655
56. Liao HX, Alam SM, Mascola JR, Robinson J, Ma B, Montefiori DC, Rhein M, Sutherland LL, Scearce R, Haynes BF (2004) Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J Virol 78: 5270–5278
57. Liu H, Geng S, Wang B, Wu B, Xie X, Wang S, Zhong Y, Wang X, Qu D, Wen Y et al (2016) Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized. Hum Vaccin Immunother 12: 77–84
58. Lizee G, Basha G, Tiong J, Julien JP, Tian M, Biron KE, Jefferies WA (2003) Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol 4: 1065–1073
59. Lu L, Xia S, Ying T, Jiang S (2015) Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerg Microbes Infect 4: e37
60. Matsubara S, Koya T, Takeda K, Joetham A, Miyahara N, Pine P, Masuda ES, Swasey CH, Gelfand EW (2006) Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 34: 426–433
61. McClintock SD, Barron AG, Olle EW, Deogracias MP, Warner RL, Opp M, Johnson KJ (2005) Role of interleukin-6 in immune complex induced models of vascular injury. Inflammation 29: 154–162
62. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14: 327–336
63. McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond M, Leusen JH, Lazarou M et al (2007) The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog 3: e72
64. Meng ZF, Wang HJ, Yao X, Wang XY, Wen YM, Dai JX, Xie YH, Xu JQ (2012) Immunization with HBsAg-Fc fusion protein induces a predominant production of Th1 cytokines and reduces HBsAg level in transgenic mice. Chin Med J (Engl) 125: 3266–3272
65. Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, Hernandez J, Piechaczyk M, Pelegrin M (2010) A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 6: e1000948
66. Moalli F, Doni A, Deban L, Zelante T, Zagarella S, Bottazzi B, Romani L, Mantovani A, Garlanda C (2010) Role of complement and Fcγ receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood 116: 5170–5180
67. Mocsai A, Ruland J, Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10: 387–402
68. Neubert K, Lehmann CH, Heger L, Baranska A, Staedtler AM, Buchholz VR, Yamazaki S, Heidkamp GF, Eissing N, Zebroski H et al (2014) Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. J Immunol 192: 5830–5838
69. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510–1512
70. Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96: 179–204
71. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34–47
72. Nimmerjahn F, Ravetch JV (2012) Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12: 13
73. Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S et al (2012) Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 72: 1672–1682
74. Nydegger UE (2007) Immune complex pathophysiology. Ann NY Acad Sci 1109: 66–83
75. Oefner CM, Winkler A, Hess C, Lorenz AK, Holecska V, Huxdorf M, Schommartz T, Petzold D, Bitterling J, Schoen AL et al (2012) Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol 129(1647–1655): e1613
76. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552–2558
77. Okuno Y, Matsumoto K, Isegawa Y, Ueda S (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68: 517–520
78. Olitzki L (1935) The antigenic properties of bacteria combined with antibodies. J Immunol 29: 453–465
79. Pan R, Chen Y, Vaine M, Hu G, Wang S, Lu S, Kong XP (2015) Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. Emerg Microbes Infect 4: e44
80. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB (2007) FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26: 67–78
81. Perreau M, Pantaleo G, Kremer EJ (2008) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205: 2717–2725
82. Pham GH, Iglesias BV, Gosselin EJ (2014) Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells. Vaccine 32: 5212–5220
83. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 8: 992–1000
84. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS (2011) Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J 9: 807–816
85. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15: 707–716
86. Platzer B, Stout M, Fiebiger E (2014) Antigen cross-presentation of immune complexes. Front Immunol 5: 140
87. Pleass RJ (2009) Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol 31: 529–538
88. Pokric B, Sladic D, Juros S, Cajavec S (1993) Application of the immune complex for immune protection against viral disease. Vaccine 11: 655–659
89. Polyanskaya N, Bergmeier LA, Sharpe SA, Cook N, Leech S, Hall G, Dennis M, ten Haaft P, Heeney J, Manca F et al (2001) Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. Virology 279: 527–538
90. Qin D, Wu J, Vora KA, Ravetch JV, Szakal AK, Manser T, Tew JG (2000) Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol 164: 6268–6275
91. Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110: 71–79
92. Rautenschlein S, Kraemer C, Montiel E, Vanmarcke J, Haase C (2007) Bilateral effects of vaccination against infectious bursal disease and Newcastle disease in specific-pathogen-free layers and commercial broiler chickens. Avian Dis 51: 14–20
93. Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9: 457–492
94. Ravetch J (2010) In vivo veritas: the surprising roles of Fc receptors in immunity. Nat Immunol 11: 183–185
95. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P et al (1999) Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371–380
96. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118: 2098–2110
97. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, Verbeek JS, Ossendorp F (2002) Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 168: 2240–2246
98. Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13: 176–189
99. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278–287
100. Sedlik C, Orbach D, Veron P, Schweighoffer E, Colucci F, Gamberale R, Ioan-Facsinay A, Verbeek S, Ricciardi-Castagnoli P, Bonnerot C et al (2003) A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol 170: 846–852
101. Shakushiro K, Yamasaki Y, Nishikawa M, Takakura Y (2004) Efficient scavenger receptor-mediated uptake and cross-presentation of negatively charged soluble antigens by dendritic cells. Immunology 112: 211–218
102. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (2011) Ipilimumab. Nat Rev Drug Discov 10: 411–412
103. St Pierre CA, Leonard D, Corvera S, Kurt-Jones EA, Finberg RW (2011) Antibodies to cell surface proteins redirect intracellular trafficking pathways. Exp Mol Pathol 91: 723–732
104. Suhrbier A, La Linn M (2003) Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 24: 165–168
105. Szakal AK, Kosco MH, Tew JG (1988a) FDC-iccosome mediated antigen delivery to germinal center B cells, antigen processing and presentation to T cells. Adv Exp Med Biol 237: 197–202
106. Szakal AK, Kosco MH, Tew JG (1988b) A novel in vivo follicular dendritic cell-dependent iccosome-mediated mechanism for delivery of antigen to antigen-processing cells. J Immunol 140: 341–353
107. Terres G, Hughes WL, Wolins W (1960) Whole-body measurement of radioactivity as a means of following in vivo the degradation of I-131-labeled proteins in mice. Am J Physiol 198: 1355–1360
108. Terres G, Wolins W (1959a) Enhanced sensitization in mice by simultaneous injection of antigen and specific rabbit antiserum. Proc Soc Exp Biol Med 102: 632–635
109. Terres G, Wolins W (1959b) Immune degradation in passively sensitized mice. I. Degradation of antigen as a function of the amount of antigen and antibody used. J Immunol 83: 9–16
110. Terres G, Wolins W (1961) Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum. J Immunol 86: 361–368
111. Tirado SM, Yoon KJ (2003) Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16: 69–86
112. Vasovic LV, Dyall R, Clynes RA, Ravetch JV, Nikolic-Zugic J (1997) Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur J Immunol 27: 374–382
113. Visciano ML, Tuen M, Gorny MK, Hioe CE (2008) In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 372: 409–420
114. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL et al (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289
115. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM (2012) Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 14: R39
116. Wang JR, Guan WD, Yau LF, Gao WN, Zhan YQ, Liu L, Yang ZF, Jiang ZH (2015a) Glycomic signatures on serum IgGs for prediction of postvaccination response. Sci Rep 5: 7648
117. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV (2015b) Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell 162: 160–169
118. Warren JS, Yabroff KR, Remick DG, Kunkel SL, Chensue SW, Kunkel RG, Johnson KJ, Ward PA (1989) Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 84: 1873–1882
119. Wen YM, Xiong SD, Zhang W (1994) Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. J Gen Virol 75: 335–339
120. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ (1995) Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345: 1575–1576
121. Wieland A, Shashidharamurthy R, Kamphorst AO, Han JH, Aubert RD, Choudhury BP, Stowell SR, Lee J, Punkosdy GA, Shlomchik MJ et al (2015) Antibody effector functions mediated by Fcgamma-receptors are compromised during persistent viral infection. Immunity 42: 367–378
122. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT (2003) HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 171: 2161–2169
123. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861
124. Wu Y, Cho M, Shore D, Song M, Choi J, Jiang T, Deng YQ, Bourgeois M, Almli L, Yang H et al (2015) A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun 6: 7708
125. Wu Y, Sukumar S, El Shikh ME, Best AM, Szakal AK, Tew JG (2008) Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J Immunol 180: 281–290
126. Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH, Wen YM (2005) Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23: 2658–2664
127. Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX et al (2008) A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 3: e2565
128. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH et al, (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59: 450–456
129. Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG (2015) Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42: 379–390
130. Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM (2007) Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25: 1771–1779
131. Yosipovich R, Aizenshtein E, Shadmon R, Krispel S, Shuster E, Pitcovski J (2015) Overcoming the susceptibility gap between maternal antibody disappearance and auto-antibody production. Vaccine 33: 472–478
132. Zheng B, Zhang Y, He H, Marinova E, Switzer K, Wansley D, Mbawuike I, Han S (2007) Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J Immunol 179: 6153–6159
133. Zheng BJ, Ng MH, He LF, Yao X, Chan KW, Yuen KY, Wen YM (2001) Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 19: 4219–4225